The pharmacological development of GLP-1 receptor agonists (GLP-1RAs) has focused on introducing specific structural modifications to enhance resistance to DPP-4 degradation, extend half-life, and improve bioavailability
11,17 However, this autoimmune disease also improved after treatment with a GLP1 RA, even before glycemic control or weight loss was achieved
A patient with significant metabolic dysfunction might benefit from standard-dose semaglutide or tirzepatide's stronger appetite suppression
Figure 10 Current Status and Future Outlook Current Recommendations Following the recent demonstration of several long-term cardiovascular outcomes trials and other new studies, the EASD/ADA position statement on management of hyperglycemia in type 2 diabetes was revised again in 2018 (141)
As experts continue to study the impact that GLP-1s have on health outcomes, state budgets, peoples lives and out-of-pocket costs, it is expected that the drugs will remain a topic of conversation among state lawmakers, Medicaid agencies, stakeholder groups and many others during the coming 2025 legislative session